These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 8026159)

  • 21. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Escherichia coli resistant to cephalosporins and quinolones is still susceptible to the cephalosporin-quinolone ester Ro 23-9424.
    Pace J; Bertasso A; Georgopapadakou NH
    Antimicrob Agents Chemother; 1991 May; 35(5):910-5. PubMed ID: 1649574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of a new cephalosporin ME-1206 compared with other agents.
    Chin NX; Zhang YX; Neu HC
    Diagn Microbiol Infect Dis; 1991; 14(5):417-24. PubMed ID: 1797456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Brucella activity of Ro 23-9424, a dual-action antibacterial.
    Qadri SM; Ueno Y; Ayub A
    Chemotherapy; 1993; 39(6):386-9. PubMed ID: 8222864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
    Barry AL; Fuchs PC
    Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
    Prosser BL; Beskid G
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):33-45. PubMed ID: 7789095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter comparative study of the in vitro activity of fleroxacin and other antimicrobial agents.
    Markowitz SM; Williams DS; Hanna CB; Parker JL; Pierce MA; Steele JC
    Chemotherapy; 1995; 41(6):477-86. PubMed ID: 8529440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mode of action of the dual-action cephalosporin Ro 23-9424.
    Georgopapadakou NH; Bertasso A; Chan KK; Chapman JS; Cleeland R; Cummings LM; Dix BA; Keith DD
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1067-71. PubMed ID: 2675755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
    Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antibacterial activity of gatifloxacin against various fresh clinical isolates in 2002].
    Matsuzaki K; Watabe E; Yoshimori K; Shikano M; Sato Y; Hasegawa M; Kobayashi I
    Jpn J Antibiot; 2002 Dec; 55(6):800-7. PubMed ID: 12621734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
    Barrett MS; Jones RN; Erwin ME; Johnson DM; Briggs BM
    Diagn Microbiol Infect Dis; 1991; 14(5):389-401. PubMed ID: 1665774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro evaluation of GR69153, a novel catechol-substituted cephalosporin.
    Erwin ME; Jones RN; Barrett MS; Briggs BM; Johnson DM
    Antimicrob Agents Chemother; 1991 May; 35(5):929-37. PubMed ID: 1854174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo evaluation of a dual-action antibacterial, Ro 23-9424, compared to cefotaxime and fleroxacin.
    Beskid G; Siebelist J; McGarry CM; Cleeland R; Chan K; Keith DD
    Chemotherapy; 1990; 36(2):109-16. PubMed ID: 2107064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative in vitro activity of the two new oral cephalosporin metabolites RO 19-5247 and RO 15-8074.
    Aldridge KE; Schiro DD; Sanders CV
    Eur J Clin Microbiol; 1987 Oct; 6(5):564-9. PubMed ID: 3436316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.